Affimed (NASDAQ:AFMD) Given Average Recommendation of “Buy” by Brokerages

Shares of Affimed (NASDAQ:AFMD) have been assigned an average recommendation of “Buy” from the four ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

AFMD has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Monday, September 9th.

Affimed Stock Up 0.9 %

Shares of NASDAQ:AFMD opened at $3.26 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.71 and a quick ratio of 2.71. Affimed has a 12-month low of $2.92 and a 12-month high of $8.95. The business has a 50 day moving average of $3.59 and a two-hundred day moving average of $4.64.

Affimed (NASDAQ:AFMD) last posted its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. As a group, research analysts expect that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Affimed stock. Choreo LLC bought a new stake in shares of Affimed (NASDAQ:AFMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned about 0.07% of Affimed at the end of the most recent reporting period. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.